866-997-4948(US-Canada Toll Free)

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Mar 2017

Category :

Pharmaceutical

No. of Pages : 50 Pages

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Hypoactive Sexual Desire Disorder Pipeline Review, H1 2017, provides an overview of the Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline landscape.

Hypoactive sexual desire disorder (HSDD) is an absence of sexual fantasies and desire for sexual activity. The predisposing factors include anxiety, depression, androgen deficiencies, and chronic debilitating illnesses, such as chronic renal failure, hyper-prolactinaemia and hypo-hyperthyroid states. Treatment includes antidepressant and hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Hypoactive Sexual Desire Disorder Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Hypoactive Sexual Desire Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Unknown stages are 2, 4 and 1 respectively.

Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Hypoactive Sexual Desire Disorder (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Hypoactive Sexual Desire Disorder (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Hypoactive Sexual Desire Disorder Overview
Female Hypoactive Sexual Desire Disorder Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Female Hypoactive Sexual Desire Disorder Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Hypoactive Sexual Desire Disorder Companies Involved in Therapeutics Development
Apricus Biosciences Inc
Emotional Brain BV
GlaxoSmithKline Plc
Palatin Technologies Inc
Valeant Pharmaceuticals International Inc
Female Hypoactive Sexual Desire Disorder Drug Profiles
(sildenafil citrate + testosterone) Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alprostadil Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-101 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bremelanotide Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gepirone hydrochloride ER Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIP-104 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPT-201 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Hypoactive Sexual Desire Disorder Dormant Projects
Female Hypoactive Sexual Desire Disorder Product Development Milestones
Featured News & Press Releases
Mar 20, 2017: Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
Feb 27, 2017: AMAG and Palatin Announce Rekynda Data Presentations at the International Society for the Study of Womens Sexual Health Annual Meeting
Nov 01, 2016: Bremelanotide Meets Co-Primary Endpoints in Palatins Phase 3 Trials for Hypoactive Sexual Desire Disorder
Sep 23, 2016: Palatin Technologies Presents Bremelanotide Neurobiology and Treatment Efficacy Review at World Meeting on Sexual Medicine
Aug 04, 2016: Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder
Nov 02, 2015: Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference
Aug 20, 2015: S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
Jul 29, 2013: S1 Biopharma Doses First Patients in Phase 2a Clinical Trial of Lorexys in Premenopausal Women with HSDD
Feb 20, 2012: S1 Pharma Submits IND Application For SIP-104 For Treatment Of Hypoactive Sexual Desire Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Female Hypoactive Sexual Desire Disorder Pipeline by Apricus Biosciences Inc, H1 2017
Female Hypoactive Sexual Desire Disorder Pipeline by Emotional Brain BV, H1 2017
Female Hypoactive Sexual Desire Disorder Pipeline by GlaxoSmithKline Plc, H1 2017
Female Hypoactive Sexual Desire Disorder Pipeline by Palatin Technologies Inc, H1 2017
Female Hypoactive Sexual Desire Disorder Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
Female Hypoactive Sexual Desire Disorder Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *